Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Bid For ZymoGenetics Looks Even Better In Light Of Promising Melanoma Data

Oct 01 2010

Related Content

Shire Emphasizes The GI Space In Its Bid For Movetis

Aug 09 2010

BMS Files Ipilimumab With FDA And EMA, Positioning It For Launch Next Year

Jul 22 2010

Weak Result Stops Pfizer’s Tremelimumab Phase III Trial

Apr 02 2008

Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B

Feb 27 2009

No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma

Apr 27 2009

From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics

Sep 07 2010

Related Companies

ZymoGenetics

Bristol Myers Squibb Company

Medarex

Madrigal Pharmaceuticals, Inc.

GSK plc

Bayer AG

Onyx Pharmaceuticals, Inc.

Pfizer Inc.

Novo Nordisk A/S

Eli Lilly and Company

Abbott

Facet Biotech

Takeda Pharmaceutical Co. Ltd.

Movetis NV

Seattle Life Sciences

Additional Topics

BioPharmaceutical

More from Archive

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window